Market Place
Sourcing Support
Sonnet Bio Releases Virtual Investor ‘”What this Means” Segment
12 Nov 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces U.S. Patent for IL-18 Variant
06 Nov 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Prices $5M Underwritten Offering
06 Nov 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
17 Oct 2024 //
GLOBENEWSWIRE
Sonnet Bio Enters into Licensing Agreement with Alkem Laboratories
09 Oct 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics To Receive Non-Dilutive Funding
04 Oct 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
30 Sep 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
25 Sep 2024 //
GLOBENEWSWIRE
Sonnet Completes Enrollment In SON-1010 Phase 1 Study
18 Sep 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
22 May 2024 //
ACCESSWIRE
Sonnet Updates SON-1010 Mono/Combo Data, Higher Dose Target
20 May 2024 //
ACCESSWIRE
Sonnet Provides Fiscal Q2 2024, YTD Business And Earnings Update
14 May 2024 //
ACCESSWIRE
Sonnet BioTherapeutics participates in EF Hutton Annual Global Conference
06 May 2024 //
ACCESSWIRE
Sonnet to Present Preclinical Data on SON-080 for (CIPN) the AACR 2024 Meeting
19 Mar 2024 //
ACCESSWIRE
Sonnet Announces Data from the Company’s Phase 1b/2a Clinical Trial of SON-080
11 Mar 2024 //
ACCESSWIRE
Sonnet Announces a Publication Demonstrating Safety of SON-1010
29 Feb 2024 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business Update
14 Feb 2024 //
ACCESSWIRE
Sonnet Bio Announces Publication Demonstrating Suitability of SON-1210
21 Dec 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
14 Dec 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
31 Oct 2023 //
ACCESSWIRE
Sonnet Announces Pricing of $4.55 Million Underwritten Public Offering
25 Oct 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation
17 Oct 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Results of Biodistribution Studies
20 Sep 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
19 Sep 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
31 Aug 2023 //
ACCESSWIRE
Sonnet Announces FDA Acceptance of IND for the SB221 Trial of SON-1010
16 Aug 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Earnings Update
14 Aug 2023 //
ACCESSWIRE
Sonnet BioTherapeutics to Present at 2023 BTIG Virtual Biotechnology Conference
31 Jul 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces $2.25 M Registered Direct Offering
28 Jun 2023 //
ACCESSWIRE
Sonnet Announces Presentations at the 2023 Cytokine-Based Drug Development
23 Jun 2023 //
ACCESSWIRE
Sonnet Announces Regulatory Approval for Initiation of a Trial of SON-1010
20 Jun 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010
18 Apr 2023 //
ACCESSWIRE
Sonnet Announces Webcast to Discuss Clinical Data from the SB101
17 Apr 2023 //
ACCESSWIRE
Sonnet to Present Data from the SB101 Study with SON-1010 at the AACR
14 Mar 2023 //
ACCESSWIRE
Sonnet Provides Fiscal Year 2023 First Quarter Business and Earnings Update
13 Feb 2023 //
ACCESSWIRE
Sonnet Announces Pricing of $15.0 Million Underwritten Public Offering
08 Feb 2023 //
ACCESSWIRE
Sonnet Announces Completion of IND-Enabling Toxicology Studies with SON-1210
01 Feb 2023 //
ACCESSWIRE
Sonnet Announces Data in a Phase 1 Dose-Escalation Trial of SON-1010
19 Jan 2023 //
ACCESSWIRE
J&J-partnered Sonnet halts work on bispecific, hunts for allies
16 Dec 2022 //
FIERCEBIOTECH
Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update
15 Dec 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Trials of SON-1010
02 Nov 2022 //
ACCESSWIRE
Sonnet Announces Webcast to Discuss Interim Data from the Company’s Phase 1
01 Nov 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Announces an Agreement with Janssen
31 Oct 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price
04 Oct 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors
26 Sep 2022 //
ACCESSWIRE
Sonnet Bio Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
22 Sep 2022 //
PRESS RELEASE
Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Update
15 Aug 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Trial of SON-1010 in Healthy Volunteers
21 Jul 2022 //
ACESSWIRE
Sonnet Bio Announces Positive Results from PC Combination Study of SON-1010
08 Jun 2022 //
ACCESSWIRE
Sonnet Bio Begins Dosing in PI Trial of SON-1010 for Advanced Solid Tumors
13 Apr 2022 //
ACCESSWIRE
Sonnet Bio Shows PC Data Supporting Bispecific Interleukin Candidates at AACR
08 Apr 2022 //
ACCESSWIRE
Sonnet Announces Successful Completion of the Discovery Phase for SON-1410
30 Aug 2021 //
BIOSPACE
Sonnet Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
16 Aug 2021 //
PRESS RELEASE
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
04 May 2021 //
BIOSPACE
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021
04 Feb 2021 //
BIOSPACE
Sonnet Completes Successful Repeat Dose Study of SON-1010
01 Feb 2021 //
NASDAQ
Sonnet Announces the Successful Completion Toxicology Study of SON-080
25 Jan 2021 //
BLOOMBERG
Sonnet BioTherapeutics Announces the Completion of a Successful
30 Nov 2020 //
APNEWS
Sonnet Announces At-The-Market Warrant Repricing and Exchange Resulting $10.5 M
04 Aug 2020 //
ACESSWIRE
Sonnet Signs Letter of Intent for Potential Licensing of Neuropathies Asset
04 Aug 2020 //
BIOSPACE
